Please take the time to read this as this sounds like an exciting and educationally beneficial course unlike any other course out there
Problem Solving Haemodialysis Academy 2010
29th and 30th November 2010 www.w12conferences.co.uk
W12 Conference Centre, Ground Floor, Hammersmith House, Hammersmith Hospital
Venue
Minutes from London’s Underground system, close to the arterial A40, an event environment has been designed specifically for the needs of delegates from the UK and around the world. With 11 comfortable, fully equipped conference rooms and associated breakout and catering facilities.
Course Fees:
Internal Nurse No charge
External Nurse £25/day
Internal Doctor £50/day
External Doctor £75/day
Consultant £100/day
Course Organisers:
Neill Duncan Peter Hill Albert Power
Anastasia Lawrence Catherine Ryan
Claire Edwards Seema Singh
Course Facilitators:
Maura Appelbe Damien Ashby Chris Baker
Wendy Brown Rawya Charif Peter Choi
Elaine Clutterbuck Richard Corbett Jeremy Crane
Elizabeth Dalby Neill Duncan
Claire Edwards
Andrew Frankel Jack Galliford Megan Griffith
Nuala Hammond Nadey Hakim Debbie Haynes
Peter Hill Nicky Kumar Anastasia Lawrence
Jeremy Levy Marina Loucaidou
Jen McDermott
Adam McLean Andrew Palmer
Vassilios Papalois
Darren Parsons Albert Power
Virginia Prout
Catherine Ryan Seema Singh
David Taube
Method of Teaching
This academy aims challenge current nursing and medical practice with the evidence base to educate and improve patient care. It is addressed to all health professionals who deliver dialysis care. We will learn by studying cases in 4 themed modules per day over 2 days. Each theme will be introduced by asking the academy to directly feed its opinion to small groups and by electronic voting to the academy as a whole. This feedback will act as a foil to identify areas for in depth analysis in lecture format from leaders in their field who will present the latest literature and illustrate their ideas with local experience.
Outline of Curriculum
Monday 29th November
Haemodialysis Technique:Home or Away and How?
We aim to offer Home-based therapy for patients. But who is this ideal for? What are the medical and patient related outcomes? How can we realise this form of therapy? Quotidian dialysis is feasible if therapy is home-based. What is it? What are the latest outcomes in trials? What extra benefit does High-flux and Haemodiafiltration have to offer in trials of Hospital-based therapy?
Iron supplementation and Erythropoeitin:Do We Harm Patients With Our Targets?
Anaemia guidelines are contentious and subject to change. How do we achieve them and does the way in which a Haemoglobin target is achieved influence outcome? We examine the evidence of benefit and risk associated with Iron and Erythropoeitin and Erythropoeitin Stimulating Agent therapy. What role does Hepcidin have in monitoring?
Long Term Haemodialysis Outcomes:How Much Better Could It Get For Patients?
Our dialysis population is growing more elderly with increasing Comorbidity and Frailty. What is the impact of this trend in Registries worldwide and our Local population? Can we identify groups of patients Who most benefit from haemodialysis? Can we identify Treatment related factors that will increase medical benefit? What are the Priorities of our Patients?
The Diabetic Patient on Haemodialysis:A Case For Special Monitoring and Treatment?
Half of our haemodialysis population has diabetes either as a cause of End Stage Renal Disease or a complicating factor. What special consideration needs to be taken with regard Monitoring Diabetes and its Complications? Can we tailor better treatment regimes with New Therapies to improve outcome? Are Patients are ahead of us, how can we catch up?
Tuesday 30th November
Facilitating Renal Transplantation:If not, why not?
Who should be transplanted, who would be better left on Haemodialysis? We will examine prejudices to wait listing. What is needed to accurately measure risk in a marginal recipient? How can we modify these risks to facilitate transplantation? How do we measure benefit?
Blood Pressure:Why and How Should We Control It?
Targets for blood pressure control are arbitrary and not rooted in a strong evidence base. Whilst we endeavour to treat hypertension as this may be associated with better outcome, prospective interventional trials are lacking. We will exam the evidence as to how blood pressure should be monitored and what are the appropriate targets? Who will benefit from treatment and how should they be treated? How should we involve patients in blood pressure management?
Infection on Dialysis:Prevention Is Better Than Cure?
The battle against the incessant threat of access related infection is endless. How do we form access and how do we care for it? What patient related factors operate? We stress the importance of continued real-time surveillance. We examine universal precautions, antibiotic strategies, exit site care and line-locks. We will also examine holiday-related infection and in particular blood-borne viruses.
Cardiovascular Death on Haemodialysis:Is All This Really Necessary?
It is widely accepted that Cardiovascular Death is the cause of mortality in half of our patients. Should this be accepted? Can we modify conventional and unconventional risk factors to improve outcome? Can we target revascularisation strategies to improve survival?
Haemodialysis 2020: Who Why and How? Invited Speaker: Ken Farrington
We welcome Dr Farrington to talk on his vision of haemodialysis treatment in the next 10 years, what patients will we be treating and with what outcomes. What technological developments does he envisage?
